semaglutide versus tirzepatide vs. Semaglutide: What You Should Know Semaglutide vs. tirzepatide: Comparing weight

We've helped countless patients look, live and feel better

Gillian Murray, MPharm, PG Dip, Clin Pharm, INP

What differs is the numbers you plug in

Table 18: Treatment Effects for the Primary Endpoints* and their Components* in the DECLARE Trial Figure 4: Time to First Occurrence of Hospitalization for Heart Failure or CV Death in the DECLARE Trial Figure 5: Time to First Occurrence of Hospitalization for Heart Failure in the DECLARE Trial Chronic Kidney Disease The Trial to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease (DAPA-CKD, NCT03036150) was an international, multicenter, randomized, double-blind, placebo-controlled trial in adult patients with chronic kidney disease (CKD) (eGFR between 25 and 75 mL/min/1.73 m) and albuminuria [urine albumin creatinine ratio (UACR) between 200 and 5000 mg/g] who were receiving standard of care background therapy, including a maximally tolerated, labeled daily dosage of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB)

Using the months before Retatrutide availability to build healthy habits creates a foundation that medication can enhance rather than replace

It should also recognize that obesity is a chronic medical condition, not a short-term character flaw